Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2182-2190
Published online before print October 22, 2007, doi: 10.1161/CIRCULATIONAHA.107.698852
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
116/19/2182    most recent
CIRCULATIONAHA.107.698852v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thorp, E.
Right arrow Articles by Tabas, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thorp, E.
Right arrow Articles by Tabas, I.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Related Collections
Right arrow Animal models of human disease
Right arrow Apoptosis
Right arrow Pathophysiology
Right arrow Cell signalling/signal transduction
Right arrow Genetically altered mice

(Circulation. 2007;116:2182-2190.)
© 2007 American Heart Association, Inc.


Vascular Medicine

Pioglitazone Increases Macrophage Apoptosis and Plaque Necrosis in Advanced Atherosclerotic Lesions of Nondiabetic Low-Density Lipoprotein Receptor–Null Mice

Edward Thorp, PhD; George Kuriakose, MSc; Yatrik M. Shah, PhD; Frank J. Gonzalez, PhD; Ira Tabas, MD, PhD

From the Departments of Medicine, Pathology and Cell Biology, and Physiology and Cellular Biophysics, Columbia University, New York, NY (E.T., G.K., I.T.), and the Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Md (Y.M.S., F.J.G.).

Correspondence to Ira Tabas, MD, PhD, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032. E-mail iat1{at}columbia.edu

Received February 24, 2007; accepted September 7, 2007.

Background— Thiazolidinediones (TZDs), which have actions that involve both peroxisome proliferator–activated receptor (PPAR)-{gamma}–dependent and –independent effects, improve insulin sensitivity in type II diabetes and inhibit early atherogenesis in mice. However, the effects of TZDs on advanced lesion progression are unknown.

Methods and Results— Pioglitazone and rosiglitazone enhanced macrophage apoptosis by a number of stimuli, including those thought to be important in advanced atherosclerosis. Macrophage death was not enhanced by non-TZD PPAR{gamma} activators, and TZD-induced apoptosis was still observed in PPAR{gamma}-deficient macrophages. In wild-type macrophages, death enhancement was associated with reduced activation of the cell-survival mediator nuclear factor-{kappa}B. TZDs also increased the ability of macrophages to phagocytically clear apoptotic cells, which is proposed to protect against plaque necrosis in advanced lesions. The mechanism of this effect was complex, involving both PPAR{gamma}-dependent and -independent mechanisms. To explore the net effect on advanced atherosclerosis in vivo, Ldlr–/– mice were fed a nondiabetogenic cholesterol-enriched diet to promote midstage lesions. Then, pioglitazone was administered with the diet for an additional 10 weeks. Aortic root lesions from the pioglitazone-treated mice showed a substantial increase in apoptotic cells and plaque necrosis compared with lesions from non–drug-treated mice.

Conclusions— The potential atheroprotective effects of TZDs conferred by insulin sensitization may be partially offset by adverse effects on advanced atherosclerosis. Because the mechanisms of the beneficial and proposed adverse effects may differ, these findings have potentially important implications for drug optimization.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
E. Thorp and I. Tabas
Differential Effects of Pioglitazone on Advanced Atherosclerotic Lesions
Am. J. Pathol., September 1, 2009; 175(3): 1348 - 1348.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
T. Seimon and I. Tabas
Mechanisms and consequences of macrophage apoptosis in atherosclerosis
J. Lipid Res., April 1, 2009; 50(Supplement): S382 - S387.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. Senokuchi, C.-P. Liang, T. A. Seimon, S. Han, M. Matsumoto, A. S. Banks, J.-H. Paik, R. A. DePinho, D. Accili, I. Tabas, et al.
Forkhead Transcription Factors (FoxOs) Promote Apoptosis of Insulin-Resistant Macrophages During Cholesterol-Induced Endoplasmic Reticulum Stress
Diabetes, November 1, 2008; 57(11): 2967 - 2976.
[Abstract] [Full Text] [PDF]